MSX2

Across TCGA pan-cancer cohorts, MSX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSX2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher MSX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MSX2 expression acts as an unfavorable survival marker.

READ, PRAD, and UCEC are the cancer types where MSX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.054	0.934	<.001	24	view →
PRAD	DFS	Median	All	0.139	0.888	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.292	0.662	.019	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSX2–READ (OS)

Open the READ breakdown →